GenoLogics Appoints Don Listwin to Board of Directors
News Feb 06, 2006
GenoLogics Life Sciences Software Inc. has announced the appointment of Don Listwin to the company’s board of directors.
Listwin is a distinguished networking industry veteran who spent a decade at Cisco Systems as Executive VP, having left the company in 2000.
Most recently, Listwin served as the former President and CEO of Openwave Systems.
In 2004, based on personal experience with family members fighting cancer, Listwin founded Canary Foundation, the only non-profit organization in the United States entirely dedicated to the early detection of cancer.
"Don Listwin’s experience and track record in growing technology companies into highly successful and profitable global ventures will strengthen our company and help us accelerate our growth plans," said Michael Ball, CEO of GenoLogics.
"He has incredible vision and is an influential figure with enormous passion in the discovery of identifiable "biomarkers" for accurate and early detection of cancer."
"Don is closely aligned with our mission to develop solutions that accelerate the prevention and cure of diseases such as cancer."
"I am very pleased to join the board of GenoLogics and be a part of its growth," says Don Listwin.
"A key to advancing research in disease prevention and detection is in managing the vast amounts of data generated and then being able to analyze and interpret that data."
"I believe the intersection of information technology and biotechnology is the way of the future and GenoLogics is very well positioned to really make a difference in this field."
Listwin is chair of the boards of Canary Foundation and Sana Security. He has previously served on the boards of Openwave, JDS Uniphase, Redback Networks, TIBCO Software, E-Tek, the Cellular Telecommunications & Internet Association (CTIA) and NetAid.
Listwin is a member of the Board of Trustees at the Fred Hutchinson Cancer Research Center in Seattle Washington.
A native of Canada, Listwin holds a B.S. in electrical engineering and an honorary doctorate of law from the University of Saskatchewan.
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE